CILcare
CILcare is a Montpellier-based biotech providing specialized auditory R&D services to pharma, biotech, medtech, and academic clients globally, while developing its own lead drug candidate CIL001 for cochlear synaptopathy and tinnitus.
- Company typePrivate
- Founded2014
- HeadquartersMontpellier, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
CILcare firmographics
Firmographics- Name
- CILcare
- Legal name
- CILcare S.A.S
- Website
- https://cilcare.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- CILcare is a Montpellier-based biotech providing specialized auditory R&D services to pharma, biotech, medtech, and academic clients globally, while developing its own lead drug candidate CIL001 for cochlear synaptopathy and tinnitus.
- Ownership category
- akta.pro rank
CILcare industry classification
Industry- Product category
- Hearing Therapeutics R&D Services
- NAICS
- Scientific Research and Development Services (5417), Other Scientific and Technical Consulting Services (54169), Custom Computer Programming Services (541511)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)
- akta.pro secondary industries
- Clinical CROs (Phase I–IV) (HLAGAAAA), Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)
Keywords
Where CILcare is headquartered
LocationHeadquarters
- HQ city
- Montpellier
- HQ country
- France
- HQ region
- Europe
Offices3 records
Markets served
CILcare business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Contract Research Services (CRO): Cilcare provides its smart R&D platform as research-for-hire to pharmaceutical companies, biotechs, medtech firms, and academic institutions in Europe, US, and Asia. Services include preclinical studies, PK/PD studies, ototoxicity testing, and regulatory support for hearing drug development.
- Proprietary Drug Development: Cilcare develops its own portfolio of drug candidates targeting cochlear synaptopathy and other auditory disorders. Lead candidate CIL001 is advancing through Phase 2a clinical trials for tinnitus and other indications.
Go-to-market motion3 records
Distribution channels3 records
Marketing channels6 records
CILcare product offering
Product offeringCore offering
CILcare is a French biotechnology company that provides contract research services (CRO) and develops proprietary drug candidates targeting hearing and ear disorders. Through its External Innovation division, it offers a comprehensive auditory R&D platform spanning in vitro, ex vivo, and in vivo pharmacological models, GLP-compliant ototoxicity studies, electrophysiology, behavioral assessments, histopathology, and surgical capabilities for pharmaceutical, biotech, medtech, and academic clients in Europe, the US, and Asia. Through its Therapeutics division, it advances its own drug pipeline, notably CIL001 for cochlear synaptopathy/tinnitus, and through its Auditory Analytics division, it operates an AI-driven platform that derives digital auditory signatures from patient measurements and biomarkers.
Product overview
CILcare is a biotech company organized into three interconnected divisions: (1) External Innovation – a comprehensive R&D platform offering pharmacological models, GLP toxicology, electrophysiology, and surgical services to support partners in developing drugs, gene/cell therapies, and medical devices for hearing disorders; (2) Therapeutics – advancing proprietary drug candidates including CIL001 (lead compound for cochlear synaptopathy/tinnitus in Phase 2a) and CIL003, leveraging AI and real-world data; and (3) Auditory Analytics – an AI-driven platform developing digital auditory signatures from auditory measurements and biomarkers for early detection of hearing impairment and associated diseases. The company conducts observational clinical studies (DIAMANT, SAPHIR) to characterize auditory profiles in specific patient populations and refine clinical trial protocols.
Differentiator
Problem solved
Functional benefit
Brands
- CILcare Auditory Analytics: AI-driven hearing analysis platform positioning hearing as a key asset of preventive medicine and global healthcare monitoring, utilizing auditory measurements to define digital auditory signatures.
- CILcare Therapeutics
- External Innovation
Products and services
- CILcare External Innovation (R&D Platform) Comprehensive contract research (CRO) R&D platform offering pharmacological models, GLP toxicology, electrophysiology (ABR, DPOAE, Wave I-V), behavioral assessments (GPIAS, PPI, tinnitus detection), histopathology, inner ear surgery, drug delivery (transtympanic, intracochlear, systemic), and biomarker studies. Used by pharmaceutical, biotech, medtech, and academic clients to evaluate drug candidates, gene therapies, cell therapies, and medical devices for hearing disorders.
- CIL001 Proprietary lead drug candidate targeting cochlear synaptopathy, the mechanism underlying difficulty understanding speech in noisy environments, tinnitus, and hyperacusis. Advancing through Phase 2a clinical evaluation for tinnitus and other indications, with clinical trials at Massachusetts General Hospital (US) and other sites.
- CILcare Auditory Analytics AI-driven analytics platform utilizing patient auditory measurements (ABR, DPOAE, speech-in-noise testing) combined with biomarkers and proprietary algorithms/deep learning to define digital auditory signatures for characterizing hearing impairments and supporting early detection of neurocognitive and inflammatory diseases. Used to inform clinical trial patient stratification and preventive medicine positioning.
Quantifiable outcome
- 26% of cognitively preserved diabetic patients presented clinical signs of hidden hearing loss in DIAMANT study
- +2 more outcomes
Companies that use CILcare
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
CILcare technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability4 records
Feature7 records
CILcare partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered flagship and core.
- SanofiflagshipUpdated license deal with Sanofi who becomes an equity holder, demonstrating deepened commitment to hearing loss therapies. Sanofi has been a long-term licensing partner for hearing-related programs.
- CBSETcoreNine-year collaboration since 2017 with CBSET, a leading preclinical biomedical research organization in Massachusetts. CBSET is tripling its laboratory capacity, enabling Cilcare to significantly scale up hearing research operations in the US. Together they offer a turnkey model for international companies seeking US market entry.
- Massachusetts General HospitalcoreClinical trial of CIL001 in tinnitus being conducted at MGH in Boston in partnership with Professor Stéphane Maison, an internationally recognized leader in auditory neuroscience. This marks the first evaluation of CIL001 in patients with chronic tinnitus on US soil.
- CTIBIOTECHcoreStrategic agreement with CTIBIOTECH and SATT AxLR to develop 3D bioprinted inner ear organoids from human induced pluripotent stem cells for pharmacological screening in hearing disorders. The OrgaEar project aims to enable mass production and reduce animal testing.
- SATT AxLRcoreTechnology transfer office supporting the OrgaEar project for 3D bioprinted inner ear organoid development in collaboration with CTIBIOTECH and Cilcare.
- University Hospital Gui de Chauliac (Montpellier)corePartner in the SAPHIR observational clinical study investigating hearing impairments in patients with mild cognitive impairment and Parkinson's disease.
- University Hospital Carémeau (Nîmes)corePartner in the SAPHIR study alongside Gui de Chauliac for multicenter, prospective clinical research on hearing and neurodegenerative diseases.
- Hospices Civils de LyoncorePartner in the SAPHIR study for investigating hearing profiles in early-stage neurodegenerative diseases across three patient groups.
- IDNC (Institute of Diabetology and Nutrition of Centre)corePrimary site for the DIAMANT observational clinical study, conducted in association with LNA Health research center, investigating hearing profiles in type 2 diabetes patients.
Scale indicators5 records
Recent moves8 records
Expansion highlights6 records
CILcare competitors and assessment
Company assessmentBroad incumbents
- Inotiv: Preclinical CRO with research models and toxicology services including hearing-related endpoints; comparable as a scaled preclinical services competitor to CILcare's CRO division.
- Charles River Laboratories: Largest preclinical CRO offering broad safety assessment and research models including ototoxicology services; comparable as a potential large-scale competitor in auditory preclinical work.
- Labcorp Drug Development: Global CRO with extensive central laboratory, bioanalytical, and early development services; comparable end-to-end clinical research services that overlap with CILcare's External Innovation offering.
Direct peers
- CBSET: Preclinical CRO partner in Massachusetts offering translational research services; directly comparable as a specialty preclinical CRO with cardiovascular/otology capabilities.
- Akouos: Gene-therapy biotech for inner-ear disorders; comparable specialty therapeutic focus on auditory drug development including modalities CILcare supports as a CRO.
- Otonomy: Clinical-stage biopharma developing drugs for ear disorders including tinnitus and hearing loss; directly comparable to CILcare's Therapeutics division and lead indication space.
- Sensorion: French clinical-stage biotech focused on hearing loss therapies including tinnitus and cochlear indications; highly comparable specialty therapeutic-area positioning to CILcare.
- Frequency Therapeutics: Clinical-stage biotech developing regenerative therapies for hearing loss; comparable therapeutic-area focus and clinical-stage profile to CILcare's CIL001 program.
- Decibel Therapeutics: Gene-therapy biotech for hearing (acquired by Eli Lilly); directly comparable therapeutic-area focus on cochlear synaptopathy and hearing regeneration pathways.
Emerging players
- Pipeline Therapeutics: Emerging biotech pursuing regenerative approaches to sensorineural hearing loss; partial overlap in therapeutic area with CILcare's lead indication.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
CILcare social profiles
Digital presenceCILcare financial estimates
Financial estimateRevenue estimate
Valuation estimate
CILcare leadership team
Management profileNumber of profiles
Profiles8 records
CILcare subsidiaries and ownership
Company hierarchySubsidiaries2 records
CILcare funding detail
Funding detailFunding overview
Funding rounds2 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CILcare M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CILcare
What does CILcare do?
CILcare is a French biotechnology company that provides contract research services (CRO) and develops proprietary drug candidates targeting hearing and ear disorders. Through its External Innovation division, it offers a comprehensive auditory R&D platform spanning in vitro, ex vivo, and in vivo pharmacological models, GLP-compliant ototoxicity studies, electrophysiology, behavioral assessments, histopathology, and surgical capabilities for pharmaceutical, biotech, medtech, and academic clients in Europe, the US, and Asia. Through its Therapeutics division, it advances its own drug pipeline, notably CIL001 for cochlear synaptopathy/tinnitus, and through its Auditory Analytics division, it operates an AI-driven platform that derives digital auditory signatures from patient measurements and biomarkers.
Is CILcare a public or private company?
CILcare is a private company. It is classified as venture growth investor backed and is currently operating.
When was CILcare founded?
CILcare was founded in 2014. It employs 11 to 50 people.
Where is CILcare based?
CILcare is headquartered in Montpellier, France, in the Europe region.
How does CILcare make money?
Two revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are proprietary Drug Development.
Who are CILcare's main competitors?
Broad incumbents on record are Inotiv, Charles River Laboratories and Labcorp Drug Development. Direct peers are CBSET, Akouos, Otonomy, Sensorion, Frequency Therapeutics and Decibel Therapeutics. Pipeline Therapeutics is listed as an emerging player.
Does CILcare have an API?
No public API is recorded for CILcare.
What industry is CILcare in?
CILcare's product category is Hearing Therapeutics R&D Services. Its primary akta.pro industry code is HLAGAAAL, Specialty Therapeutic-Area CROs (e.g., oncology/rare disease), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 5417 and its SIC code is 2834.